<DOC>
	<DOCNO>NCT01746875</DOCNO>
	<brief_summary>The purpose study determine treatment effect patient retinal pigment epithelium detachment ( PED ) relation Age Related Maculopathy ( AMD ) . Patients newly diagnose PED without choroidal neovascularisations ( CNV ) , randomize either treatment observation . The treatment group first give injection anti Vascular Endothelium Growth Factor ( anti-VEGF ) . If injection effect , Verteporfin Photodynamic Therapy ( PDT ) give . All patient follow period 2 year . It hypothesize treatment stop progression disease stabilize vision subgroup patient AMD .</brief_summary>
	<brief_title>A Study Testing Medicine Can Make Pigment Epithelium Detachments Regress Stabilize Vision Eyes</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Pigment epithelium detachment eye earlier treated antiVEGF verteporfin PDT . ETDRS Best Corrected Visual acuity 20/32 20/400 Prior treatment verteporfin , externalbeam radiation therapy , transpupillary thermotherapy , Previous subfoveal focal laser photocoagulation involve foveal center , History vitrectomy , submacular surgery , surgical intervention AMD . CNV , Subfoveal fibrosis atrophy study eye . Concurrent eye disease study eye could compromise visual acuity ( e.g. , diabetic retinopathy , advanced glaucoma ) require medical surgical intervention study . Active intraocular inflammation study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Angiogenesis inhibitor</keyword>
	<keyword>Photochemotherapy</keyword>
	<keyword>Vascular Endothelium Growth Factors</keyword>
	<keyword>Aflibercept</keyword>
</DOC>